Partial duplication of chromosome 17 syndrome
par-shuhl doo-pli-kay-shun of kroh-muh-sohm sev-en-teen sin-drohm
Also known as: 17q duplication syndrome, Chromosome 17q trisomy
At a Glance
What is Partial duplication of chromosome 17 syndrome?
Partial duplication of chromosome 17 syndrome is a rare genetic disorder caused by an extra copy of a segment of chromosome 17. This condition affects multiple body systems, including the neurological and musculoskeletal systems. It is typically caused by a random genetic mutation, although it can sometimes be inherited from a parent. Over time, individuals may experience developmental delays, intellectual disabilities, and physical abnormalities. Early symptoms often include feeding difficulties and hypotonia, while later symptoms may involve behavioral issues and learning disabilities. Early diagnosis is crucial for managing symptoms and improving quality of life. The condition can have a significant impact on family life, requiring ongoing medical care and support. Prognosis varies depending on the severity of symptoms, but many individuals can lead fulfilling lives with appropriate interventions. Daily life for affected individuals often involves specialized education and therapy services. Support from healthcare professionals and community resources is essential for managing the condition. Families may benefit from genetic counseling to understand the risks and implications of the disorder.
Medical Definition
Partial duplication of chromosome 17 syndrome is characterized by the presence of an additional copy of a portion of the long arm of chromosome 17. Pathologically, this results in an imbalance of genetic material, leading to a range of clinical manifestations. Histological findings may include abnormal neuronal development and connective tissue anomalies. The syndrome is classified under chromosomal duplication disorders and is considered extremely rare, with an estimated prevalence of 1 in 1,000,000. Epidemiologically, it can occur as a de novo mutation or be inherited in an autosomal dominant pattern. The disease course is variable, with symptoms ranging from mild to severe, and management focuses on symptomatic treatment and supportive care.
Partial duplication of chromosome 17 syndrome Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Developmental delay manifests as a significant lag in reaching milestones such as walking or speaking. It is caused by the disruption of normal gene expression due to the chromosomal duplication. Over time, the delay may become more apparent as peers continue to develop at a typical pace. Daily life is affected as the child may require special education and therapies to aid in development.
Intellectual disability presents as below-average cognitive functioning and challenges in adaptive behaviors. This occurs due to the overexpression of genes on the duplicated chromosome segment. The severity can range from mild to severe and may become more evident as educational demands increase with age. It impacts daily life by necessitating individualized learning plans and support for daily activities.
Facial dysmorphism includes distinct facial features such as a broad forehead, flat nasal bridge, and downturned mouth. These features result from abnormal craniofacial development influenced by genetic imbalances. The dysmorphic features typically remain consistent throughout life. They can affect self-esteem and social interactions, but supportive counseling and cosmetic interventions may help.
Common
Hypotonia is characterized by decreased muscle tone, leading to a floppy appearance. It is caused by disruptions in neuromuscular signaling pathways due to genetic anomalies. Over time, hypotonia may improve with physical therapy but can persist into adulthood. It affects motor skills and physical activities, requiring ongoing physiotherapy and support.
Seizures manifest as sudden, uncontrolled electrical disturbances in the brain. They occur due to abnormal neuronal activity linked to genetic imbalances. Seizures can vary in frequency and severity, sometimes becoming more manageable with medication. They impact daily life by necessitating medical management and precautions to prevent injury during episodes.
Congenital heart defects involve structural abnormalities of the heart present at birth. These defects arise from disrupted cardiac development during embryogenesis. The severity of heart defects can range from mild to life-threatening, often requiring surgical intervention. They affect daily life by potentially limiting physical activity and requiring ongoing medical care.
Less Common
Hearing loss can range from mild to profound and may affect one or both ears. It results from malformations or dysfunctions in the auditory system due to genetic anomalies. Over time, hearing loss can lead to delays in speech and language development if not addressed. It impacts communication, necessitating hearing aids or other auditory support devices.
Vision problems may include issues such as strabismus or refractive errors. These occur due to abnormal eye development influenced by genetic factors. Vision problems may worsen or stabilize over time, depending on the underlying cause. They affect daily life by requiring corrective lenses or surgical interventions to improve visual acuity.
What Causes Partial duplication of chromosome 17 syndrome?
Partial duplication of chromosome 17 syndrome is primarily caused by duplications involving the 17p13.3 region, which includes the PAFAH1B1 gene. PAFAH1B1 encodes the LIS1 protein, crucial for proper neuronal migration during brain development. Mutations or duplications in PAFAH1B1 lead to overexpression or altered function of LIS1, disrupting microtubule dynamics. This disruption affects intracellular transport and mitotic spindle orientation, impairing cell division and differentiation. Consequently, neuronal migration is defective, leading to cortical malformations such as lissencephaly. These structural brain abnormalities contribute to neurological symptoms, including developmental delay and seizures. The immune response may be activated due to abnormal neuronal signaling, exacerbating neuroinflammation. Over time, neuroinflammation can lead to white matter degeneration, further impairing cognitive and motor functions. The specific pattern of symptoms is influenced by the extent and location of the duplication, affecting different brain regions variably. Variability in disease severity among patients is attributed to differences in the size of the duplication and the involvement of additional genes. Other genes within the duplicated region, such as YWHAE, may also contribute to the phenotype by affecting cell signaling pathways. The combination of genetic and environmental factors further modulates the clinical presentation. Understanding the precise genetic and molecular mechanisms is crucial for developing targeted therapies. Current research focuses on identifying additional genetic modifiers and therapeutic targets. Early diagnosis and intervention can improve outcomes by addressing specific symptoms and supporting neurodevelopment.
How is Partial duplication of chromosome 17 syndrome Diagnosed?
Typical age of diagnosis: Partial duplication of chromosome 17 syndrome is typically diagnosed in infancy or early childhood when developmental delays and congenital anomalies become apparent. Diagnosis often occurs after initial clinical evaluations and genetic counseling due to the presence of multiple congenital anomalies.
Clinicians look for developmental delays, congenital anomalies, and dysmorphic features. A detailed family history is important to identify any hereditary patterns. Physical examination may reveal features such as craniofacial dysmorphisms, limb abnormalities, or growth retardation. This step helps to identify the need for further genetic testing and imaging studies.
Magnetic Resonance Imaging (MRI) is commonly used to assess structural brain abnormalities. Specific abnormalities such as ventriculomegaly or corpus callosum agenesis may be visible. These findings help confirm the diagnosis by correlating clinical features with structural anomalies. Imaging also helps exclude other conditions with similar phenotypic presentations.
Chromosomal microarray analysis is often ordered to detect chromosomal duplications. Biomarkers such as elevated levels of certain metabolites may be sought in blood tests. Abnormal results might show an extra copy of a segment of chromosome 17. These results guide the decision to perform more detailed genetic testing.
Array comparative genomic hybridization (aCGH) is used to sequence the chromosome. Duplications involving the 17p or 17q regions are identified. The presence of these duplications confirms the diagnosis of partial duplication of chromosome 17 syndrome. Genetic results also inform family counseling regarding recurrence risks and implications for other family members.
Partial duplication of chromosome 17 syndrome Treatment Options
Anticonvulsants are used to manage seizure activity, which may occur in this condition. These drugs work by stabilizing neuronal membranes and reducing excitability. Commonly used anticonvulsants include valproate and levetiracetam. Clinical evidence supports their efficacy in reducing seizure frequency, though individual response can vary. Side effects may include sedation, liver dysfunction, and weight gain.
Techniques such as motor skills training and sensory integration are used. The goal is to improve motor function and sensory processing. Sessions are typically conducted 2-3 times per week for several months. Measurable outcomes include improved coordination and muscle strength. Long-term benefits include enhanced functional independence and quality of life.
Surgery may be indicated for congenital anomalies such as cleft palate or limb deformities. The procedure involves reconstructive techniques to restore normal anatomy. Expected benefits include improved function and appearance. Surgical risks include infection, anesthesia complications, and need for revision surgery. Post-operative care includes pain management and physical rehabilitation.
The care team includes geneticists, neurologists, physical therapists, and psychologists. Interventions focus on developmental support, seizure management, and nutritional guidance. Psychosocial support strategies involve counseling and support groups for families. Family education covers condition management and available resources. Long-term monitoring involves regular assessments to track developmental progress and adjust care plans.
When to See a Doctor for Partial duplication of chromosome 17 syndrome
- Severe difficulty breathing — this could indicate a life-threatening respiratory issue requiring immediate medical attention.
- Sudden loss of consciousness — this may be a sign of a serious neurological event or cardiac problem.
- Severe, unrelenting pain — this could be indicative of an acute medical emergency that needs urgent evaluation.
- Persistent vomiting — could lead to dehydration and requires medical evaluation.
- Unexplained weight loss — may indicate a metabolic or systemic issue that needs investigation.
- Frequent infections — could suggest an underlying immune deficiency that warrants further testing.
- Mild fatigue — monitor for worsening symptoms and ensure adequate rest and nutrition.
- Occasional headaches — keep a diary of frequency and triggers to discuss with your doctor if they persist.
Partial duplication of chromosome 17 syndrome — Frequently Asked Questions
Is this condition hereditary?
Partial duplication of chromosome 17 syndrome can be hereditary, often following an autosomal dominant pattern. There is a 50% chance of passing the condition to offspring if one parent is affected. De novo mutations, which occur spontaneously, are also possible. Carrier status may not always be apparent without genetic testing. Genetic counseling is recommended to understand inheritance patterns and reproductive options.
What is the life expectancy for someone with this condition?
Life expectancy varies depending on the severity of symptoms and associated health issues. Early intervention and management of complications can improve outcomes. Respiratory and cardiac complications are common causes of mortality. Treatment can significantly enhance quality of life and survival. Realistic expectations should be discussed with a healthcare provider, considering individual circumstances.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis typically involves genetic testing, such as chromosomal microarray analysis or karyotyping. The time from first symptoms to diagnosis can vary, often taking several months. Geneticists and genetic counselors are usually involved in the diagnostic process. Delays in diagnosis can occur due to the rarity and variability of symptoms. A confirmed diagnosis is made once genetic testing identifies the chromosomal duplication.
Are there any new treatments or clinical trials available?
Research is ongoing, with gene therapy and targeted molecular treatments showing promise. Clinical trials can be found on ClinicalTrials.gov by searching for chromosome 17 duplication. Patients should discuss potential participation in trials with their doctor. It's important to ask about the risks, benefits, and eligibility criteria. New treatments may take several years to become widely available.
How does this condition affect daily life and activities?
The condition can impact mobility and self-care, depending on the severity of physical symptoms. Educational challenges may arise due to developmental delays or learning disabilities. Social and emotional challenges are common, affecting both the individual and their family. The burden on families can be significant, requiring support and adaptations. Access to therapies, educational support, and community resources can greatly assist in daily life.
Learn More
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.Genetic analysis of partial duplication of the long arm of chromosome 16.
Tang D, Chen A, Xu J et al. · BMC Med Genomics · 2024 · PMID: 39716170
- 2.Molecular cytogenetic characterization of partial trisomy of the long arm of chromosome 11 in a patient with multiple congenital anomalies.
Walker A, Wang X, Kim YM et al. · Mol Cytogenet · 2022 · PMID: 35440058
- 3.Genetic Analysis of 17q Terminal Partial Trisomy.
Zheng H, Zheng L, Huang Z et al. · Clin Case Rep · 2024 · PMID: 39619310
- 4.Genotype-phenotype analysis of recombinant chromosome 4 syndrome: an array-CGH study and literature review.
Hemmat M, Hemmat O, Anguiano A et al. · Mol Cytogenet · 2013 · PMID: 23639048
- 5.Partial duplication of 18q including a distal critical region for Edwards Syndrome in a patient with normal phenotype and oligoasthenospermia: case report.
Quiroga R, Monfort S, Oltra S et al. · Cytogenet Genome Res · 2011 · PMID: 21228546
- 6.DNA rearrangements on both homologues of chromosome 17 in a mildly delayed individual with a family history of autosomal dominant carpal tunnel syndrome.
Potocki L, Chen KS, Koeuth T et al. · Am J Hum Genet · 1999 · PMID: 9973284
- 7.New insights on partial trisomy 3q syndrome: de novo 3q27.1-q29 duplication in a newborn with pre and postnatal overgrowth and assisted reproductive conception.
Serra G, Antona V, Cimador M et al. · Ital J Pediatr · 2023 · PMID: 36759911
- 8.Duplication of the Miller-Dieker Critical Region in a Patient with a Subtelomeric Unbalanced Translocation t(10;17)(p15.3;p13.3).
Ruiz Esparza-Garrido R, Velázquez-Wong AC, Araujo-Solís MA et al. · Mol Syndromol · 2012 · PMID: 23326253
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-05-19